Structure of hepatitis B virus core protein and disablement in the hepatitis B antiviral therapy

Abstract

Abstract: Core protein which is encoded by the hepatitis B virus (HBV) c gene can package the pre-genome mRNA to form nucleocapsid and play a key role in the HBV replication. The disablement of core protein by RNA interference, core protein antibody and core protein mutant can block capsid formation, inhibit HBV replication. This can be used as a new target for hepatitis B antiviral therapy.

Key words: Hepatitis B virus, Core protein, Nucleocapsid, Disablement

CLC Number:

R512.6

LIU Xue-ni, PAN Qing-chun, ZANG Guo-qing, YU Yong-sheng. Structure of hepatitis B virus core protein and disablement in the hepatitis B antiviral therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1170-1173.

References

[1] Garcia ML, Byfield R, Robek MD. Hepatitis B virus replication and release are independent of core lysine ubiquitination[J]. J Virol, 2009,83(10):4923-4933.
[2] He XX, Lin JS, Chang Y, et al. Effects of two novel nucleoside analogues on different hepatitis B virus promoters[J]. World J Gastroenterol, 2008,14(12):1836-1841.
[3] Choi IG, Yu YG. Interaction and assembly of HBV structural proteins: novel target sites of anti-HBV agents[J]. Infect Disord Drug Targets, 2007,7(3):251-256.
[4] Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein[J]. J Virol, 1997,71(1):345-353.
[5] Bruss V. Envelopment of the hepatitis B virus nucleocapsid[J]. Virus Res, 2004,106(2):199-209.
[6] Pairan A, Bruss V. Functional surfaces of the hepatitis B virus capsid[J]. J Virol, 2009,83(22):11616-11623.
[7] Bruss V.Hepatitis B virus morphogenesis[J].World J Gastroenterol, 2007,13(1):65-73.
[8] Hilmer JK, Zlotnick A, Bothner B. Conformational equilibria and rates of localized motion within hepatitis B virus capsids[J]. J Mol Biol, 2008,375(2):581-594.
[9] Günther S, Piwon N, Jung A,et al. Enhanced replication contributes to enrichment of hepatitis B virus with a deletion in the core gene[J]. Virology, 2000,273(2):286-299.
[10] Ying RS, Zhu C, Fan XG, et al. Hepatitis B virus is inhibited by RNA interference in cell culture and in mice[J]. Antiviral Res, 2007,73(1):24-30.
[11] Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference[J]. Hepatology, 2003,37(4):764-770.
[12] 余永胜,陈有华.抗乙型肝炎病毒基因治疗的若干进展[J].中国临床药理学与治疗学,2002,7(6):574-576.
[13] Luk JM, Wong KF. Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma[J]. Clin Exp Pharmacol Physiol, 2006,33(5/6):482-488.
[14] Filpula D. Antibody engineering and modification technologies[J]. Biomol Eng, 2007,24(2):201-215.
[15] 邸雅南,胡大荣,胡学玲. HBV C基因截短型突变体抗HBV作用研究[J].中华传染病学杂志,2005,23(5):293-296.
[16] Zlotnick A, Ceres P, Singh S, et al. A small molecule inhibits and misdirects assembly of hepatitis B virus capsids[J]. J Virol, 2002,76(10):4848-4854.
[17] Deres K, Schröder CH, Paessens A, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nuclecocapsids[J]. Science, 2003, 299(5608):893-896.